A PYMNTS Company

US: Court weighs whether to let Actavis drop Alzheimer’s drug

By  |  April 13, 2015

Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer’s drug in favor of a pricier extended-release version, a move that New York’s attorney general has said would suppress generic competition.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    A three-judge panel of the 2nd U.S. Circuit Court of Appeals peppered attorneys for Actavis and for the attorney general with questions, although the judges gave no clear indication of how they would rule.

    New York Attorney General Eric Schneiderman filed an antitrust lawsuit against Dublin-based Actavis last year in Manhattan federal court after the company said it was planning to discontinue Namenda IR in favor of Namenda XR. The two drugs have the same active ingredient, but Namenda XR is taken once daily instead of twice.

    The lawsuit claimed that by forcing patients to switch to the new version, Actavis hoped to stave off competition from drug maker.

     

    Full Content: Houston Chronicle

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.